Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

Casebia’s VP of Strategy and BD, Peter Nell, participated in an exciting panel today at #BIOEuropeSpring to discuss “Commercialization of Cell and Gene Therapies”.

“In the future #CRISPR can be used for risk reduction, for example of heart attacks” - Peter Nell of @casebiatx - #BIOEuropeSpring

See us on Twitter